The International Journal of Neuropsychopharmacology
June 28, 2011
Matthew R. Skelton, Devon L Graham, Tori L. Schaefer et al.
8 citations
Previous findings showed allocentric and egocentric learning deficits in rats after MDMA treatment from postnatal days (PD) 11-20 but not after treatment from PD 1-10. Shorter treatment periods (PD 1-5, 6-10, 11-15, or 16-20) resulted in allocentric learning deficits averaged across intervals but not for any interval individually and no egocentric learning deficits individually or collectively....
Pharmaceuticals
June 17, 2011
Vivian Capilla‐González, Vicente Hernández‐rabaza
4 citations
The capacity of the brain to generate new adult neurons is a recent discovery that challenges the old theory of an immutable adult brain. A new and fascinating field of research now focuses on this regenerative process. The two brain systems that constantly produce new adult neurons, known as the adult neurogenic systems, are the dentate gyrus (DG) of the hippocampus and the lateral...
Clinical Pharmacology & Therapeutics
June 15, 2011
Cédric M. Hysek, Linda D. Simmler, M. Ineichen et al.
153 citations
This study assessed the pharmacodynamic and pharmacokinetic effects of the interaction between the selective norepinephrine (NE) transporter inhibitor reboxetine and 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in 16 healthy subjects. The study used a double-blind, placebo-controlled crossover design. Reboxetine reduced the effects of MDMA including elevations in plasma levels of NE,...
Archives of General Psychiatry
June 6, 2011
David Erritzøe, Vibe G. Frøkjær, Klaus K. Holst et al.
86 citations
We found evidence that MDMA but not hallucinogen use is associated with changes in the cerebral presynaptic serotonergic transmitter system. Because hallucinogenic drugs primarily have serotonin(2A) receptor agonistic actions, we conclude that the negative association between MDMA use and cerebral SERT binding is mediated through a direct presynaptic MDMA effect rather than by the serotonin(2A)...
Radiology
June 3, 2011
Hua-Shan Liu, Ming‐Chung Chou, Hsiao‐Wen Chung et al.
20 citations
PURPOSE: To investigate the effects of 3,4-methylenedioxymethamphetamine (MDMA, commonly known as "ecstasy") on the alterations of brain metabolites and anatomic tissue integrity related to the function of the basal ganglia-thalamocortical circuit by using proton magnetic resonance (MR) spectroscopy and diffusion-tensor MR imaging. MATERIALS AND METHODS: This study was approved by a local...
Synapse
June 3, 2011
Michael W. McLane, Una D. Mccann, George A. Ricaurte
11 citations
A number of published studies have questioned the serotonin neurotoxic potential of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and related drugs (fenfluramine, p-chloroamphetamine) based upon results from Western blot studies using a custom synthesized serotonin transporter (SERT) antibody that found no reduction in the abundance of a 50kDa protein after substituted amphetamine...
Addiction
June 3, 2011
A. C. Parrott
12 citations
Halpern et al. 1 presented some interesting findings from a study of abstinent ecstasy users in Salt Lake City, USA. Their ecstasy group reported comparatively slight use of all psychoactive drugs, both legal and illicit, and were therefore different from the typical user who often takes a range of other drugs. Their control group comprised similar-aged occasional rave attendees, who had never...
Human Psychopharmacology Clinical and Experimental
June 1, 2011
John E. Fisk, Catharine Montgomery, Florentia Hadjiefthyvoulou
13 citations
OBJECTIVE: Previous research suggests that ecstasy users are impaired in processing visuospatial information. However, for the most part, the deficits observed appear to involve the recall and recognition of complex visual and geometric patterns. The present research sought to determine whether ecstasy use was associated with deficits in serial spatial recall and visuospatial working memory...
Psychopharmacology
June 2011
Andrew C. Parrott, Amy Gibbs, Andrew Scholey et al.
This study investigated the acute mood effects of oral MDMA, methamphetamine, and placebo in a double-blind laboratory study. Fifty-two healthy participants comprised abstinent recreational users of stimulant drugs, 27 female and 25 male, mean age 24.8 years. Three test sessions involved acute 100 mg oral 3.4-methylendioxymethamphetamine (MDMA), 0.42 mg/kg oral methamphetamine, and matching...
Current Drug Abuse Reviews
June 1, 2011
Sybille Schulz
15 citations
Although the prevalence of co-use of cannabis and 3,4 methylenedioxymethamphetamine (MDMA) is very common among polydrug users in western societies, few studies have tested the consequences on behavior, cognition or neurobiology. This review examines 23 articles published between 2002 and 2010 with an explicit focus on the combination, or administration, of MDMA and cannabis or cannabinoid...